IL158821A0 - Combination medicament for treatment of neoplastic diseases - Google Patents
Combination medicament for treatment of neoplastic diseasesInfo
- Publication number
- IL158821A0 IL158821A0 IL15882102A IL15882102A IL158821A0 IL 158821 A0 IL158821 A0 IL 158821A0 IL 15882102 A IL15882102 A IL 15882102A IL 15882102 A IL15882102 A IL 15882102A IL 158821 A0 IL158821 A0 IL 158821A0
- Authority
- IL
- Israel
- Prior art keywords
- alkoxycarbonyl
- alkoxy
- amino
- sulfo
- trifluoromethyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- -1 nitro, sulfo, cyano, amino Chemical group 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29292801P | 2001-05-24 | 2001-05-24 | |
| PCT/DK2002/000351 WO2002094322A2 (fr) | 2001-05-24 | 2002-05-24 | Medicaments combinatoires utilises dans le traitement de maladies neoplasiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158821A0 true IL158821A0 (en) | 2004-05-12 |
Family
ID=23126850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15882102A IL158821A0 (en) | 2001-05-24 | 2002-05-24 | Combination medicament for treatment of neoplastic diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030045515A1 (fr) |
| EP (1) | EP1411984B1 (fr) |
| JP (1) | JP2005508857A (fr) |
| KR (1) | KR20040007607A (fr) |
| CN (1) | CN1516600A (fr) |
| AT (1) | ATE394100T1 (fr) |
| AU (1) | AU2002316795B2 (fr) |
| BR (1) | BR0209936A (fr) |
| CA (1) | CA2449442A1 (fr) |
| CZ (1) | CZ20033189A3 (fr) |
| DE (1) | DE60226446D1 (fr) |
| HU (1) | HUP0400024A3 (fr) |
| IL (1) | IL158821A0 (fr) |
| MX (1) | MXPA03010691A (fr) |
| PL (1) | PL366462A1 (fr) |
| RU (1) | RU2291710C2 (fr) |
| WO (1) | WO2002094322A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2290454T3 (es) * | 2002-05-17 | 2008-02-16 | Leo Pharma A/S | Profarmacos de cianoguanidina. |
| PL372761A1 (en) * | 2002-05-17 | 2005-08-08 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| AU2003295773A1 (en) * | 2002-11-21 | 2004-06-18 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| WO2005009354A2 (fr) * | 2003-07-17 | 2005-02-03 | Pharmacia Corporation | Compositions contenant un inhibiteur selectif de la cyclooxygenase-2 et un inhibiteur des ikk, utilisees dans le traitement des troubles ou lesions d'origine ischemique du systeme nerveux central |
| AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| CA2594508C (fr) | 2004-12-22 | 2013-10-01 | Leo Pharma A/S | Composes de 1-cyanoguanidine |
| CA2613068A1 (fr) | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Indole carboxamides en tant qu'inhibiteurs d'ikk2 |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| JP2009502996A (ja) * | 2005-08-04 | 2009-01-29 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ＩＫＫ−β阻害剤との組合せ |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| CA2721927C (fr) | 2008-04-21 | 2014-01-28 | Otonomy, Inc. | Preparations auriculaires de traitement de maladies et etats otiques |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| CA2751495C (fr) * | 2009-02-06 | 2013-08-20 | Tianjin Hemay Bio-Tech Co., Ltd. | Compositions pharmaceutiques contenant des pyridyl-cyanoguanidines, leurs methodes de preparation et utilisations |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| WO2012031199A1 (fr) | 2010-09-03 | 2012-03-08 | Forma Therapeutics, Inc. | Composés et compositions de guanidine pour l'inhibition de nampt |
| CA2990835A1 (fr) * | 2015-06-23 | 2016-12-29 | Case Western Reserve University | Compositions et methodes pour le traitement du cancer |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219472D0 (en) * | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| GB9711119D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711122D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
-
2002
- 2002-05-21 US US10/151,094 patent/US20030045515A1/en not_active Abandoned
- 2002-05-24 PL PL02366462A patent/PL366462A1/xx not_active Application Discontinuation
- 2002-05-24 IL IL15882102A patent/IL158821A0/xx unknown
- 2002-05-24 EP EP02745167A patent/EP1411984B1/fr not_active Expired - Lifetime
- 2002-05-24 CA CA002449442A patent/CA2449442A1/fr not_active Abandoned
- 2002-05-24 AU AU2002316795A patent/AU2002316795B2/en not_active Ceased
- 2002-05-24 WO PCT/DK2002/000351 patent/WO2002094322A2/fr active IP Right Grant
- 2002-05-24 CN CNA028121880A patent/CN1516600A/zh active Pending
- 2002-05-24 JP JP2002591038A patent/JP2005508857A/ja not_active Withdrawn
- 2002-05-24 AT AT02745167T patent/ATE394100T1/de not_active IP Right Cessation
- 2002-05-24 BR BR0209936-5A patent/BR0209936A/pt not_active IP Right Cessation
- 2002-05-24 CZ CZ20033189A patent/CZ20033189A3/cs unknown
- 2002-05-24 MX MXPA03010691A patent/MXPA03010691A/es unknown
- 2002-05-24 HU HU0400024A patent/HUP0400024A3/hu unknown
- 2002-05-24 KR KR10-2003-7015363A patent/KR20040007607A/ko not_active Application Discontinuation
- 2002-05-24 DE DE60226446T patent/DE60226446D1/de not_active Expired - Fee Related
- 2002-05-24 RU RU2003137006/15A patent/RU2291710C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094322A3 (fr) | 2004-02-26 |
| DE60226446D1 (de) | 2008-06-19 |
| CZ20033189A3 (cs) | 2004-12-15 |
| CN1516600A (zh) | 2004-07-28 |
| EP1411984B1 (fr) | 2008-05-07 |
| US20030045515A1 (en) | 2003-03-06 |
| PL366462A1 (en) | 2005-02-07 |
| HUP0400024A2 (hu) | 2004-04-28 |
| RU2291710C2 (ru) | 2007-01-20 |
| WO2002094322A2 (fr) | 2002-11-28 |
| RU2003137006A (ru) | 2005-04-10 |
| BR0209936A (pt) | 2004-04-06 |
| AU2002316795B2 (en) | 2007-08-02 |
| JP2005508857A (ja) | 2005-04-07 |
| KR20040007607A (ko) | 2004-01-24 |
| HUP0400024A3 (en) | 2007-05-29 |
| MXPA03010691A (es) | 2004-07-01 |
| CA2449442A1 (fr) | 2002-11-28 |
| ATE394100T1 (de) | 2008-05-15 |
| EP1411984A2 (fr) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL158821A0 (en) | Combination medicament for treatment of neoplastic diseases | |
| TR200001279T2 (tr) | Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler. | |
| ATE303357T1 (de) | Amid-derivate | |
| WO2003091259A8 (fr) | Inhibiteurs de la triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase | |
| HRP20130664T1 (en) | Heterocyclic aspartyl protease inhibitors | |
| AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
| TR199801151T2 (xx) | Trombin inhibit�r� �n ila�lar. | |
| DK0778834T3 (da) | Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2 | |
| NO20032233L (no) | Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer | |
| GEP20053692B (en) | Substituted Alkylamine Derivatives and Methods of Use | |
| WO2002034753A3 (fr) | Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione | |
| ES2188005T3 (es) | Derivados de amidas para el tratamiento de enfermedades mediadas por citoquinas. | |
| EA200200306A1 (ru) | Трициклические ингибиторы поли(адф-рибозо)полимераз | |
| HRP20090159T1 (en) | Use of glucosidase inhibitors for therapy of mucovisidosis | |
| BR9813767A (pt) | Processo e composição para tratar glaucoma de glc1a | |
| ATE362912T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| WO2000055124A3 (fr) | Composes et compositions utilises comme inhibiteurs de protease | |
| AU5650901A (en) | Cyclohexane derivatives and their use as therapeutic agents | |
| AP1564A (en) | Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use. | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| ATE277897T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| AU5493296A (en) | 6-carboxamido dihydropyran derivatives | |
| RS20060280A (en) | Novel keto-oxadiazole derivatives as cathepsin inhibitors | |
| MXPA03010766A (es) | Nuevos compuestos y composiciones como inhibicores de las catepsinas. | |
| ATE278663T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha |